News

Researchers at Flinders University in Australia identified a new potential biomarkers in the urine of patients with amyloid lateral sclerosis (ALS).

Researchers in the U.S. showed that thanks to a computer-brain interface device that they developed people with different forms of paralysis, including amyloid lateral sclerosis (ALS), can type using direct brain controls faster than was previously possible.

People who eat fish and seafood containing high concentrations of mercury may be more likely to develop amyotrophic lateral sclerosis (ALS), a new preliminary study suggests. Researchers will present their study’s findings at the American Academy of Neurology’s 69th Annual Meeting, set for April 22-28 in Boston. The question isn’t whether people should…

People who have amyotrophic lateral sclerosis (ALS) know how hard it can be to communicate, but a new app developed by Microsoft researchers, called GazeSpeak, may make speaking with the eyes a reality. GazeSpeak, to be unveiled in May at the Conference on Human Factors in Computing…

Researchers have developed a method to measure the effectiveness of a process of RNA destruction that clears abnormal molecules from cells. Since abnormally high production of junk RNA has been thought to contribute to amyotrophic lateral sclerosis (ALS), the method can be used to screen for drugs that may boost…

The fitness franchise Orangetheory Fitness has partnered with Augie’s Quest to raise $1 million over the next two weeks for amyotrophic lateral sclerosis (ALS) research. During the campaign (#IBurnForALS) — which lasts from February 20 to March 5 — more than 570 Orangetheory studios nationwide will encourage their members…

If parents pass on mutations in the C9orf72 gene, their children not only develop amyotrophic lateral sclerosis (ALS) or frontotemporal dementia but do so at an earlier age due to an expansion of the mutation. This finding makes it easier for physicians to determine when to start monitoring an individual carrying a C9orf72…

Two French researchers, Martine Barkats and Maria-Grazia Biferi, are winners of the Avi Kremer ALS Treatment Prize, worth $1 million, for developing a gene therapy approach that shows promise in treating certain types of amyotrophic lateral sclerosis (ALS), Prize4Life announced in a recent press release. The approach targets one of the…

Neuraltus Pharmaceuticals has enrolled 50 of the 120 patients it hopes to obtain for a confirmatory Phase 2 clinical trial evaluating NP001 as a treatment for amyotrophic lateral sclerosis (ALS). Completion of enrollment is expected in mid-2017, with Neuraltus shooting for results in early 2018. Eighteen clinical sites across North…

Researchers have developed a molecule called 123C4 that targets the EphA4 receptor, which is known to contribute to the development of amyotrophic lateral sclerosis (ALS), according to a new study. The paper, “Potent and Selective Epha4 Agonists for the Treatment of ALS,” appeared in the journal Cell Chemical Biology. Its…